MedPath

Topotecan

Generic Name
Topotecan
Brand Names
Hycamtin, Potactasol, Topotecan Hospira
Drug Type
Small Molecule
Chemical Formula
C23H23N3O5
CAS Number
123948-87-8
Unique Ingredient Identifier
7M7YKX2N15
Background

An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.

Indication

用于小细胞肺癌（SCLC）和一线治疗失败的晚期转移性卵巢癌。

Associated Conditions
Acute Myeloid Leukemia, Ewing's Sarcoma, Refractory Neuroblastoma, Metastatic Rhabdomyosarcoma, Recurrent Stage IVB Cervical Cancer, Refractory CNS lymphoma, Refractory CNS malignancy, Refractory, metastatic Ovarian cancer, Relapsed Platinum Sensitive Small Cell Lung Cancer (SCLC)
Clinical Trials
Related News

Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)

Phase 2
Completed
Conditions
Small-cell Lung Cancer
Interventions
First Posted Date
2021-02-24
Last Posted Date
2023-08-15
Lead Sponsor
EMD Serono Research & Development Institute, Inc.
Target Recruit Count
76
Registration Number
NCT04768296
Locations
🇺🇸

National Cancer Institute, Bethesda, Maryland, United States

🇺🇸

FirstHealth of the Carolinas, Inc., Pinehurst, North Carolina, United States

🇺🇸

Summa Health, Akron, Ohio, United States

and more 48 locations

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Phase 2
Active, not recruiting
Conditions
Fallopian Tube Mucinous Adenocarcinoma
Ovarian Seromucinous Carcinoma
Platinum-Refractory Fallopian Tube Carcinoma
Platinum-Refractory Ovarian Carcinoma
Platinum-Refractory Primary Peritoneal Carcinoma
Recurrent Fallopian Tube Clear Cell Adenocarcinoma
Recurrent Fallopian Tube Endometrioid Adenocarcinoma
Recurrent Fallopian Tube High Grade Serous Adenocarcinoma
Recurrent Fallopian Tube Mucinous Adenocarcinoma
Recurrent Fallopian Tube Transitional Cell Carcinoma
Interventions
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Computed Tomography with Contrast
Procedure: Echocardiography Test
Procedure: Magnetic Resonance Imaging
Procedure: Multigated Acquisition Scan
First Posted Date
2021-02-05
Last Posted Date
2025-04-23
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
120
Registration Number
NCT04739800
Locations
🇺🇸

CoxHealth South Hospital, Springfield, Missouri, United States

🇺🇸

Missouri Baptist Sullivan Hospital, Sullivan, Missouri, United States

🇺🇸

TriHealth Cancer Institute-Westside, Cincinnati, Ohio, United States

and more 388 locations

Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

First Posted Date
2021-01-06
Last Posted Date
2025-03-12
Lead Sponsor
Seagen, a wholly owned subsidiary of Pfizer
Target Recruit Count
502
Registration Number
NCT04697628
Locations
🇺🇸

Willis-Knighton Physician Network/Gynecologic Oncology Associates, Shreveport, Louisiana, United States

🇺🇸

Maryland Oncology Hematology, P.A., Columbia, Maryland, United States

🇮🇹

Fondazione Policlinico Universitario Agostino, Roma, Other, Italy

and more 189 locations

Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

First Posted Date
2020-12-22
Last Posted Date
2021-08-27
Lead Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Target Recruit Count
427
Registration Number
NCT04679064
Locations
🇮🇹

Istituto Tumori della Romagna IRST IRCCS, Meldola, Italy

🇮🇹

Azienda Ospedaliera Spedali Civili, Brescia, Italy

🇮🇹

IEO-Istituto Europeo di Oncologia, Milan, Italy

and more 5 locations

Cabozantinib With Topotecan-Cyclophosphamide

Phase 1
Completed
Conditions
Relapsed Ewing Sarcoma
Refractory Ewing Sarcoma
Relapsed Osteosarcoma
Refractory Osteosarcoma
Interventions
Drug: Myeloid growth factor
First Posted Date
2020-12-10
Last Posted Date
2023-02-15
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
12
Registration Number
NCT04661852
Locations
🇺🇸

Boston Children's Hospital, Boston, Massachusetts, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

Phase 1
Active, not recruiting
Conditions
Metastatic Malignant Solid Neoplasm
Metastatic Pancreatic Adenocarcinoma
Unresectable Malignant Solid Neoplasm
Unresectable Neuroendocrine Carcinoma
Unresectable Pancreatic Adenocarcinoma
Stage IV Lung Cancer AJCC v8
Metastatic Lung Small Cell Carcinoma
Metastatic Neuroendocrine Carcinoma
Stage III Lung Cancer AJCC v8
Stage III Pancreatic Cancer AJCC v8
Interventions
Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
First Posted Date
2020-08-17
Last Posted Date
2025-03-06
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
28
Registration Number
NCT04514497
Locations
🇺🇸

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States

🇺🇸

Smilow Cancer Hospital Care Center-Trumbull, Trumbull, Connecticut, United States

🇺🇸

Mayo Clinic in Florida, Jacksonville, Florida, United States

and more 20 locations

A Prospective International Multicenter Clinical Trial for Eyes With Relapsed Retinoblastoma

Phase 2
Terminated
Conditions
Eye Cancer, Retinoblastoma
Interventions
First Posted Date
2020-07-02
Last Posted Date
2023-10-03
Lead Sponsor
Prof. Beck Popovic Maja
Target Recruit Count
2
Registration Number
NCT04455139
Locations
🇨🇭

CHUV Lausanne University Hospital, Lausanne, Switzerland

Topotecan Episcleral Plaque for Treatment of Retinoblastoma

Phase 1
Completed
Conditions
Retinoblastoma
Interventions
First Posted Date
2020-06-11
Last Posted Date
2024-12-13
Lead Sponsor
The Hospital for Sick Children
Target Recruit Count
26
Registration Number
NCT04428879
Locations
🇨🇦

The Hospital for Sick Children, Toronto, Ontario, Canada

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

Phase 2
Recruiting
Conditions
Anaplastic Kidney Wilms Tumor
Stage III Kidney Wilms Tumor
Recurrent Kidney Wilms Tumor
Stage II Kidney Wilms Tumor
Stage IV Kidney Wilms Tumor
Interventions
Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Bone Scan
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
Radiation: Radiation Therapy
Procedure: Surgical Procedure
Procedure: Transabdominal Ultrasound
Procedure: X-Ray Imaging
First Posted Date
2020-03-26
Last Posted Date
2025-04-30
Lead Sponsor
Children's Oncology Group
Target Recruit Count
256
Registration Number
NCT04322318
Locations
🇺🇸

Children's Hospital of Alabama, Birmingham, Alabama, United States

🇺🇸

USA Health Strada Patient Care Center, Mobile, Alabama, United States

🇺🇸

Providence Alaska Medical Center, Anchorage, Alaska, United States

and more 196 locations

9-ING-41 in Pediatric Patients with Refractory Malignancies.

Phase 1
Recruiting
Conditions
Cancer Pediatric
Pediatric Cancer
Pediatric Brain Tumor
Refractory Cancer
Refractory Tumor
Pediatric Meningioma
Neuroblastoma
Neuroblastoma Recurrent
Refractory Neoplasm
Pediatric Lymphoma
Interventions
First Posted Date
2020-01-23
Last Posted Date
2024-11-08
Lead Sponsor
Actuate Therapeutics Inc.
Target Recruit Count
68
Registration Number
NCT04239092
Locations
🇺🇸

University of California, San Francisco, San Francisco, California, United States

🇺🇸

Children's Hospital Colorado, Aurora, Colorado, United States

🇺🇸

University of Chicago, Chicago, Illinois, United States

and more 6 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy